A Randomized Trial of Ivermectin Versus Albendazole for the Treatment of Cutaneous Larva Migrans

View More View Less
  • Departement de Maladies Infectieuses, Parasitaires, Tropicales et Sante Publique, Hopital de la Pitie-Salpetriere, Merck, Sharp and Dohme, Paris, France

In an open study, we compared the efficacy of single doses of oral ivermectin (12 mg) and oral albendazole (400 mg) for the treatment of cutaneous larva migrans. Twenty-one patients were randomly assigned to receive ivermectin (n = 10) or albendazole (n = 11). All patients who received ivermectin responded and none relapsed (cure rate = 100%). All but one patient in the group receiving albendazole responded, but five relapsed after a mean of 11 days (cure rate = 46%; P = 0.017). No major adverse effects were observed. We conclude that a single 12-mg dose of ivermectin is more effective than a single 400-mg dose of albendazole for the treatment of cutaneous larva migrans.